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At the moment only early detection of lung cancer offers a good prognosis for the patients.
Conventional white light endoscopy is mostly insufficient for early diagnosis. Therefore we
developed a system of fluorescence diagnosis using 5-aminolaevulinic acid (ALA)
exogeneously applied. As precursor ofthe heme synthesis it is metabolized to protoporphyrin
IX a red fluorescent substance. Therefore protoporphyrin IX accumulates in tumorous and
premalignant tissue, and can be directly visualized by fluorescence bronchoscopy. Excitation
with blue light (380-435 nm) causes a red fluorescence, which can be detected after filtering
most of the blue component with the naked eye or a camera system. After earlier work with
laser systems and cold light sources we now use the system D-Light AF for the fluorescence
diagnosis using ALA-induced protoporphyrin IX fluorescence.
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INTRODUCTION
Lung cancer is a very common disease throughout
the world, which has a dismal prognosis. The
incidence of lung cancer is still rising in most parts
ofthe world. Only early stages oflung cancer can be
cured with a high probability [1]. Therefore tools for
screening and early diagnosis are necessary [2]. For
non-invasive screening X-ray of the thorax and
sputum cytology were applied [3-7] and got incon-
clusive results. Therefore these methods are now
reexamined [8]. In the meantime the computed
tomography of the thorax is investigated [9] and
improvements of the sputum cytology were devel-
oped like immune cytology using antibody staining
and automated morphometrical analyses [10,11].
If there are suspicious results or the patient has a
history suggesting a lung cancer, bronchoscopy is
done. But bronchoscopy has a low sensitivity for
early changes [12]. Therefore methods for improv-
ing the detection of early lesions are needed. Apart
from autofluorescence systems (see [13,14] and
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other articles in this issue) active fluorescence
detection using photosensitizers is used. Early work
was done with hematoporphyrin derivatives in
therapeutic dosages [15-17], but these efforts were
limited by the skin phototoxicity of these sub-
stances. Therefore more sophisticated methods
using two-wavelength systems or time-gated
systems were applied [18-20]. The introduction of
5-aminolaevulinic acid (5-ALA) as an endogeneous
photosensitizer [21] has changed the field and allows
a very simple system for photodynamic detection of
early tumorous or premalignant lesions in various
organs such as the bladder [22] and the brain [23].
MATERIALS AND METHODS
Mechanism of 5-Aminlaevulinic Acid Induced
Protopophyrin IX Fluorescence
5-aminolaevulinic acid is a naturally occurring sub-
stance which is normally synthesized from succinyl
Co A and glycin. This synthesis is negatively regu-
lated by the presence of heme. If 5-ALA is applied
exogeneously, this negative feed-back mechanism is
surpassed and protoporphyrin IX is synthesized
during theheme biosynthesis. Figure demonstrates
schematically the principles of the accumulation of
protoporphyrin IX in the tumorous tissue.
The pharmacokinetics of the protoporphyrin IX
synthesis and metabolism are much more suited to
FIGURE Demonstration of the principles of the accumu-
lation of protoporphyrin IX in the tumorous tissue.
clinical applications than for, as an example, those
of hematoporphyrin derivatives. After 24 h even
with high systemic dosages of 5-ALA, there are no
relevant, higher levels of protoporphyrin IX in the
skin or the systemic circulation. After inhalation
there are only very small levels detectable during a
one day period [24,25]. The mechanisms for the
relatively selective accumulation ofprotoporphyrin
IX’are not quite understood, but are at least partly
caused by different enzyme activities between
malignant and normal cells.
Three-dimensional Cell Culture Systems
After the first reports ofthe use of5-ALA on the skin
and in the bladder we decided to examine the
application of 5-ALA in the bronchial system. We
examined the application of5-ALA in three-dimen-
sional miniorgans [26], which are derived from
biopsies of the bronchial wall. For these experi-
ments these biopsies are taken in routine broncho-
scopies and cultivated for 14 days. We found that
after a short exposition 5-ALA is metabolized in
these cultures with normal epithelium to protopor-
phyrin IX. This process has its maximum between
one and two hours [27].
We were further interested in whether there is a
difference between the normal epithelium and
tumorous tissue. For these purposes we established
a three-dimensional coculture system between the
above-described system and invading tumor cells
[28]. We found after a short exposition of 15 min a
clear difference between the normal epithelium and
the tumor. The maximum difference between the
normal and the tumorous tissue was between about
100 and 200 min [29].
Figure 2 demonstrates an example of a coculture
with the enhanced red fluorescence in the tumorous
areas in contrast to the normal epithelium.
Animal Experiments
In animal experiments with beagle dogs with
induced tumors, we found after nebulization of 5-
ALA a clear and visible difference between the
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As 5-ALA is an acid, we were concerned about the
possibility of bronchoconstriction after inhalation
of this substance. We tested this situation in beagle
dogs and found no evidence for a bronchoconstric-
tion through the nebulization which lasted over
10 min with 25% 5-ALA diluted in saline. Figure 3
demonstrates as an example of the lung function
parameters the course of resistance.
FIGURE 2 Example of a coculture with the enhanced red
fluorescence in the tumorous areas in contrast to the normal
epithelium.
PRELIMINARY CLINICAL RESULTS
In more than 100 patients with an established or
suspected lung cancer, we were able to demonstrate
that the inhalation of 200mg of 5-ALA (Company
Medac GmbH, Hamburg, Germany) diluted in 5 ml
NaC1 0.9% by a conventional jet nebulizer (Com-
pany Pari-Medanz, Starnberg, Germany) or a
volume and flow controlled inhalation device for a
homogenous deposition (GSF-Inhaler: Institute for
Inhalation Biology H. Schulz, P. Brand) with a
dose of 60mg in 2.5 ml NaC1 0.9% is feasible and
safe. There are no side effects apart from the
occasional cough in these mostly bronchitic
patients. Figure 4 shows as an example the peak
flow values ofour first patients which demonstrates
no deterioration of the individual values.
The results ofour in vitro study regarding the best
time interval between inhalation and photodynamic
diagnosis are now being evaluated in patients in a
Phase-I-study using the D-Light AF-system from
Storz (in cooperation with the company Medac). In
the same study we are evaluating the differences
between the two types of inhalation (Klinikum
Innenstadt: jet nebulization with the Pari-Inhaler;
Hospital for Pneumology, Mtinchen-Gauting: opti-
mized deposition with the GSF-Inhaler). About 90-
120 min after inhalation, we conduct bronchoscopy
mostly with flexible endoscopes. Rigid endoscopes
are used in combination with a camera and
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FIGURE 3 Course of airway resistance during nebulization
of 5-ALA in a beagle dog.
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FIGURE 4 Peak flow values during and after inhalation of 5-
ALA demonstrating no relevant effect on pulmonary function.116 R.M. HUBER et al.
tangential illumination which is a little bit more
non-specific.
As protoporphyrin IX can be bleached by too
much light, we begin the examination with theALA-
mode. After this we perform a routine white light
bronchoscopy. We take biopsies from all suspect
regions on the white light bronchoscopy and the
fluorescence bronchoscopy. Apart from these visi-
ble areas, random biopsies are also taken.
The method is very sensitive. Apart from big and
necrotic tumors, all tumors, carcinomata in situ, and
severe dysplastic areas show a positive red fluores-
cence. But there are also cases, in up to 50% of the
circumscript areas of red fluorescence, which are
only bronchitic or only mildly dysplastic. There are
suggestions that these lesions are highly proliferat-
ing or genetically altered regions of the epithelium
according to the findings in urology [30].
Since autofluorescene excitation ranges from 380
to 460 nm, fluorescence of protoporphyrin IX can
be seen together with the autofluorescence. Our first
experiments in patients show that the fluorescence
diagnosis using protoporphyrin IX fluorescence and
autofluorescence is possible and feasible. Whether
we really get a better specificity using a combination
with autofluorescence (AF-mode/AF-filters) is
being tested in a pilot-study.
Figure 5 demonstrates a normal fluorescence of a
bronchus in a bronchoscopic picture. In Figure 6(a)
and (b) the bronchoscopic pictures of a pathologic
fluorescence and the corresponding white light
bronchoscopy of a neoplastic lesion can be seen.
FIGURE 5 Bronchoscopic picture of a normal fluorescence
of a bronchus.
FIGURE 6 Bronchoscopic pictures of a pathologic fluores-
cence (a) and the corresponding white light bronchoscopy (b)
of a neoplastic lesion.LUNG CANCER DETECTION BY 5-ALA 117
FIGURE 7 Spectral data of normal (green line) and severely
dysplastic epithelium (red line). The ratio is about 3: 1.
Figure 7 illustrates spectral data of a normal
epithelium and a severe dysplasia. The ratio is about
3 for the severe dysplasia. The great difference and
the good optical conditions result in a high contrast
between the blue fluorescence of the normal tissue
and the specific red fluorescence oftumorous tissue.
DISCUSSION
induced by exogeneously applied ALA is that the
bronchoscopy can only be done some time (about
90-120 min) after the inhalation of 5-ALA. The
effects of autofluorescence are mostly determined
from the tissue and the morphological changes,
whereas protoporphyrin IX-fluorescence is further
determined by metabolic processes and probably
more tumor dependent/specific. So there should be
differences between the two methods. A combina-
tion of the two methods could enhance the specifi-
city of tumor detection by fluorescence methods.
The 5-ALA-induced fluorescence is further useful
for the planning ofphotodynamic therapy, as it can
demonstrate the area which should be illuminated.
We believe that there should be a prospective
randomized comparison between the two methods.
Further the combination of autofluorescence and
protoporphyrin fluorescence, induced by ALA
should be thoroughly evaluated.
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Lung cancer is a very serious health problem. Only
early therapy offers a chance for cure. For optimal
therapy it is further very important to know the
exact borders of the tumor and not to miss other
endobronchial neoplastic areas. Apart from non-
invasive screening methods we need therefore better
bronchoscopic techniques. For example the con-
ventional white light bronchoscopy misses carcino-
mata in situ in up to 70% of the cases [12]. Earlier
solutions using pharmacological fluorescence of
tumorous areas were very complicated and expen-
sive. Now we have two methods applicable in the
daily routine: the autofluorescence and the fluores-
cence of protoporphyrin IX induced by exogen-
eously applied 5-ALA. 5-aminolaevulinic acid can
be applied by simple inhalation, but of course can
also be applied systemically, if there is photo-
dynamic therapy with 5-ALA planned. A relative
disadvantage of the protoporphyrin fluorescence
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